Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer
- PMID: 6272989
Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer
Abstract
Receptors for 1,25-dihydroxyvitamin D3 have been shown to exist in cultured breast cancer cells and in primary breast cancers. It is reported here that 1,25-dihydroxyvitamin D3 receptor (1,25-DR) was present in 80% of 54 unselected breast cancers. The concentration of 1,25-DR in the 43 receptor-positive tumors was 1.9 +/- 0.4 fmol/mg protein (S.E.). There was no correlation between 1,25-DR presence or concentration and the age of the patient or the concentration of estrogen, progesterone, androgen, or glucocorticoid receptors. 1,25-DR was also found in two of three renal cortical carcinomas but only in three of 14 gastrointestinal tract carcinomas. The relatively low concentration of 1,25-DR in these breast cancers, compared with that found in cultured breast cancer cells, is partially explained by incomplete "exchange" with occupied receptors. Since the serum vitamin D-binding protein is not precipitated from serum itself or from tissue homogenates using the polyethylene glycol method, artifactual 1,25-DR levels due to the inevitable contamination of tissue specimens with this protein can be excluded. These findings indicate that 1,25-DR is not a nonspecific marker of cancer. The high frequency of 1,25-DR in the breast cancers may be related to the calcium-transporting ability of breast cancer cells which allows them to grow as osteolytic metastases.
Similar articles
-
Calcitonin and 1,25-dihydroxyvitamin D3 receptors in human breast cancer cell lines.Cancer Res. 1980 Dec;40(12):4764-7. Cancer Res. 1980. PMID: 6254651
-
Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers.Cancer Res. 1986 Oct;46(10):5406-8. Cancer Res. 1986. PMID: 3019526
-
Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.Cancer Res. 1982 Mar;42(3):1116-9. Cancer Res. 1982. PMID: 6277475
-
Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices.Cancer Res. 1984 Apr;44(4):1677-81. Cancer Res. 1984. PMID: 6322984
-
1,25-dihydroxyvitamin D3 and breast cancer.Aust N Z J Surg. 1984 Feb;54(1):17-20. Aust N Z J Surg. 1984. PMID: 6326729
Cited by
-
1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.Breast Cancer Res Treat. 1992;22(2):133-40. doi: 10.1007/BF01833343. Breast Cancer Res Treat. 1992. PMID: 1391978
-
Combined effects of 1,25-dihydroxyvitamin D3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells.Breast Cancer Res Treat. 1994 Feb;29(2):161-8. doi: 10.1007/BF00665677. Breast Cancer Res Treat. 1994. PMID: 8012034
-
Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.BMC Cancer. 2006 Mar 16;6:68. doi: 10.1186/1471-2407-6-68. BMC Cancer. 2006. PMID: 16542425 Free PMC article.
-
Calcitriol and cancer therapy: A missed opportunity.Bone Rep. 2018 Jun 13;9:110-119. doi: 10.1016/j.bonr.2018.06.002. eCollection 2018 Dec. Bone Rep. 2018. PMID: 30591928 Free PMC article.
-
Assessment of functional variants and expression of long noncoding RNAs in vitamin D receptor signaling in breast cancer.Cancer Manag Res. 2018 Sep 12;10:3451-3462. doi: 10.2147/CMAR.S174244. eCollection 2018. Cancer Manag Res. 2018. PMID: 30254488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical